A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.

PHASE2TerminatedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Diabetic Neuropathies
Interventions
DRUG

Placebo

Oral tablet once a day dosing for 10 weeks.

DRUG

[S,S]-Reboxetine

Oral tablet once a day dosing for 10 weeks.

Trial Locations (56)

1820

Pfizer Investigational Site, Ennerdale

4000

Pfizer Investigational Site, Durban

4450

Pfizer Investigational Site, KwaDukuza

6850

Pfizer Investigational Site, Worcester

7130

Pfizer Investigational Site, Cape Town

9301

Pfizer Investigational Site, Bloemfontein

10021

Pfizer Investigational Site, New York

10024

Pfizer Investigational Site, New York

14209

Pfizer Investigational Site, Buffalo

15110

Pfizer Investigational Site, Lahti

15706

Pfizer Investigational Site, Santiago de Compostela

28040

Pfizer Investigational Site, Madrid

29572

Pfizer Investigational Site, Myrtle Beach

33609

Pfizer Investigational Site, Tampa

33880

Pfizer Investigational Site, Winter Haven

35235

Pfizer Investigational Site, Birmingham

36071

Pfizer Investigational Site, Pontevedra

36207

Pfizer Investigational Site, Anniston

38133

Pfizer Investigational Site, Bartlett

38801

Pfizer Investigational Site, Tupelo

39202

Pfizer Investigational Site, Jackson

40213

Pfizer Investigational Site, Louisville

40503

Pfizer Investigational Site, Lexington

46014

Pfizer Investigational Site, Valencia

53209

Pfizer Investigational Site, Milwaukee

65705

Pfizer Investigational Site, Marionville

65807

Pfizer Investigational Site, Springfield

67100

Pfizer Investigational Site, Kokkola

75230

Pfizer Investigational Site, Dallas

75246

Pfizer Investigational Site, Dallas

77079

Pfizer Investigational Site, Houston

77081

Pfizer Investigational Site, Houston

77701

Pfizer Investigational Site, Beaumont

77706

Pfizer Investigational Site, Beaumont

80209

Pfizer Investigational Site, Denver

92691

Pfizer Investigational Site, Mission Viejo

06050

Pfizer Investigational Site, New Britain

06708

Pfizer Investigational Site, Waterbury

02747

Pfizer Investigational Site, North Dartmouth

07207

Pfizer Investigational Site, Elizabeth

08690

Pfizer Investigational Site, Hamilton

02920

Pfizer Investigational Site, Cranston

02864

Pfizer Investigational Site, Cumberland

75390-8858

Pfizer Investigational Site, Dallas

636 00

Pfizer Investigational Site, Brno

370 87

Pfizer Investigational Site, České Budějovice

702 00

Pfizer Investigational Site, Ostrava

760 01

Pfizer Investigational Site, Zlín

00290

Pfizer Investigational Site, Helsinki

08200

Pfizer Investigational Site, Lohja

1311 RL

Pfizer Investigational Site, Almere Stad

1105 AZ

Pfizer Investigational Site, Amsterdam

5912 BL

Pfizer Investigational Site, Venlo

0204

Pfizer Investigational Site, Pretoria

08907

Pfizer Investigational Site, L'Hospitalet de Llobregat

08035

Pfizer Investigational Site, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00625833 - A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy. | Biotech Hunter | Biotech Hunter